BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » How Much Revenue Does Cord Blood Registry (CBR) Generate Per Year?
CRB Revenue from Cord Blood and Tissue Storage

How Much Revenue Does Cord Blood Registry (CBR) Generate Per Year?

February 13, 2018 By Cade Hildreth (CEO)

Without a doubt, the three largest cord blood banks in the U.S. are:

Discover class-defining bioproduction tools.
  1. Cord Blood Registry (San Bruno, CA)
  2. Cryo-Cell (Oldsmar, FL)
  3. ViaCord (Waltham, MA)

These three companies are not only the three market leaders in the U.S. by number of cord blood and cord tissue units banked, but are also some of the largest cord blood banks worldwide.

Among these three industry leaders, Cord Blood Registry (CBR) is the clear leader. To date, it has preserved approximately 700,000 umbilical cord blood and cord tissue units. This is substantially more than its nearest competitor, Cryo-Cell, which recently reported in its Third Quarter 2017 results that it has reached 500,00 units in storage collected across 87 countries. ViaCord has at least 360,000 units in storage and likely closer to 400,000, because it hasn’t reported new storage metrics in the past 12 months.

In a historic event that occurred in June 2015, CBR was acquired by the pharmaceutical giant, AMAG Pharmaceuticals, for $700 million. The transaction valued Cord Blood Registry at over 5.55 times revenue and over 15.55 times EBITDA.

RoosterCollect EV Pro

The acquisition of CBR by AMAG Pharmaceuticals was a strategic move to bolster AMAG’s portfolio of maternal health products and to expand its reach by leveraging CBR’s established sales network within Ob/Gyn clinics, hospitals, and labor units throughout the United States.

Because BioInformant is the first and only market research firm to specialize in the stem cell industry, we have tracked the cord blood banking market for more than a decade (2006 to present). For this reason, we are uniquely interested to know CBR’s full-year 2017 revenue derived from cord blood and tissue banking services.

From our perspective, the main upside of CBR’s acquisition by AMAG Pharmaceuticals is that CBR’s revenue figures are now publicly reported.

How much revenue did AMAG generate from CBR’s cord blood and tissue banking in 2017?

To answer this question, we dug into AMAG Pharmaceuticals’ U.S. SEC Form 8-K released January 8, 2018.

It states:

“AMAG expects 2017 total….CBR service revenue of approximately $114 million.” 

AMAG Pharmaceuticals also reported that “Cord Blood Registry® (CBR) service revenue was approximately $30 million” during 4th Quarter 2017.”

This suggests that the company’s revenue was not evenly distributed over the course of the year, because $30 million x 4 would have equaled $120 million (instead of $114 million).

In other interesting news, Bloomberg recently reported (in a paid access article) that AMAG may be weighing the possibility of the sale of CBR, stating that: “AMAG Pharma (NASDAQ: AMAG) is exploring options including a sale of its Cord Blood Registry business following interest from potential buyers, according to Bloomberg…”

To learn more, view AMAG’s Form 8-K or the claim the “Complete 2017-18 Global Cord Blood Banking Industry Report.” Global Cord Blood Banking Industry Report

Rate this post

Filed Under: Cord Blood Tagged With: AMAG Pharma, Cord Blood Registry

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Stem cell conferences

The Complete Guide To Virtual Stem Cell Conferences in 2021

CO.DON AG

The New CO.DON Plant for the EU-approved Advanced Therapy Cartilage Regeneration Treatment Sets a Milestone in Cell Therapy for Commercial Manufacturing

Safety Chart | The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.